NASDAQ · CNTX
Context Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CNTX: Nov 4, 2026
Context Therapeutics Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.09. The reported EPS for the same quarter last year was $-0.1.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.09 | $-0.07 | $-0.11 | 3 |
| Dec 2026 | $-0.09 | $-0.08 | $-0.11 | 3 |
| Mar 2027 | $-0.10 | $-0.08 | $-0.13 | 2 |
| Jun 2027 | $-0.09 | $-0.08 | $-0.10 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel- Zacks · Oct 15, 3:47 AM EDTNew Strong Sell Stocks for October 15thCDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.
- Zacks · Oct 13, 5:19 AM EDTNew Strong Sell Stocks for October 13thATS, CANG and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2026.
- RTTNews · Sep 9, 11:47 AM EDTContext Doses First Patient In Phase 1 For Cancer Drug CT-202(RTTNews) – Context Therapeutics Inc. (CNTX), a clinical-stage biopharmaceutical company, announcement on Wednesday the dosing of the first patient in the Phase 1 trial for CT-202 in treating Nectin-4 positive tumors. Nectin-4 is a cell surface protein present on cells of solid
- RTTNews · Aug 6, 3:06 AM EDTContext Expands Q2 Net Loss As Pipeline Advances; Stock Drops 23% In Overnight Market(RTTNews) – Context Therapeutics Inc. (CNTX) reported financial results for the second quarter ended June 30, 2026, reflecting a wider year-over-year loss as it prepares to progress its clinical pipeline. The company also highlighted various upcoming milestones.
- RTTNews · Jul 7, 6:16 AM EDTContext Gains Addition To Russell 2000 And Russell 3000 Indices(RTTNews) – Context Therapeutics Inc. (CNTX), a clinical-stage biopharmaceutical company, on Monday announced the addition of the company to the small-cap Russell 2000 and Russell 3000 indices as on June 26, 2026.
- RTTNews · Jun 15, 8:43 AM EDTContext Therapeutics Reports Encouraging Early Responses In Phase 1 Trial Of CTIM-76(RTTNews) – Context Therapeutics Inc. (CNTX) announced encouraging interim results from its ongoing Phase 1 clinical trial of CTIM-76, showing early signs of anti-tumor activity in patients with heavily pretreated ovarian cancer.
- RTTNews · May 7, 5:15 AM EDTContext Records $8 Mln Loss In Q1; Advances Bispecific Antibody Programs For Cancer Treatment(RTTNews) – Context Therapeutics Inc. (CNTX), a clinical-stage biopharmaceutical company, on Wednesday released first quarter financial results, and provided updates on therapies currently in the pipeline.
- RTTNews · Apr 2, 7:46 AM EDTContext Therapeutics Gains FDA Fast Track Status For CTIM-76 In Ovarian Cancer(RTTNews) – Context Therapeutics Inc. (CNTX) on Thursday said the U.S. Food and Drug Administration has granted Fast Track Designation to its drug candidate CTIM-76 for the treatment of platinum-resistant ovarian cancer in patients who have exhausted standard therapies.
- Fintel · Mar 26, 10:35 PM EDTContext Therapeutics (CNTX) Price Target Increased by 13.33% to 5.78The average one-year price target for Context Therapeutics (NasdaqCM:CNTX) has been revised to $5.78 / share. This is an increase of 13.33% from the prior estimate of $5.10 dated February 21, 2026. The price target is an average of many targets provided by ana
- RTTNews · Mar 24, 3:29 AM EDTContext Plans To Report CTIM-76 Interim Phase 1a Data In June 2026; FY25 Net Loss Widens(RTTNews) – Context Therapeutics Inc. (CNTX), a clinical-stage biopharmaceutical company, reported its full-year 2025 financial results, reflecting a wider net loss, and outlined upcoming milestones across its investigational pipeline targeting solid tumours.
- RTTNews · Jan 5, 9:23 PM ESTAfter-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains(RTTNews) – Several biotechnology and pharmaceutical names posted notable gains in after-hours trading on Monday, driven by clinical trial updates, regulatory progress, and investor anticipation ahead of key data releases.
- Fintel · Dec 22, 4:24 PM ESTJones Trading Initiates Coverage of Context Therapeutics (CNTX) with Buy RecommendationFintel reports that on December 22, 2025, Jones Trading initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a Buy recommendation. Analyst Price Forecast Suggests 328.34% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Context Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.